Is Krishna Institute of Medical Sciences (KIMS) overvalued or fairly valued?

MarketChacha shows Krishna Institute of Medical Sciences's valuation in context — a forward P/E of about 45.9, a price-to-book of about 14.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Krishna Institute of Medical Sciences's revenue?

Krishna Institute of Medical Sciences reported revenue of ₹3,905 Cr for FY2026, with net profit of ₹241 Cr, per official filings.

What is the share price of Krishna Institute of Medical Sciences (KIMS)?

Krishna Institute of Medical Sciences last traded at ₹784.45 (-0.5% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Krishna Institute of Medical Sciences

KIMS · NSE · Healthcare · India

₹784.45-0.5%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 9:59 AM

Snapshot

TickerKIMS

ExchangeNSE

SectorHealthcare

IndustryMedical Care Facilities

CountryIndia

HeadquartersSecunderabad, India

Market cap₹31,389 Cr

P/B14.0

Volume6.09L

Websitewww.kimshospitals.com

Filings tracked0

About Krishna Institute of Medical Sciences

Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand in India. The company offers arthroscopy and shoulder, cardiology, cardiothoracic and cardiovascular, organ transplant, medical and surgical gastroenterology, hepatology, orthopaedic, neurology, neurosurgery, nephrology, urology, oncology, pediatric, neonatology, obstetrics and gynaecology, fertility, dental science, emergency and critical care, vascular, rehabilitation and physiotherapy services. It also provides pulmonology, diagnostic and imaging, ophthalmology, ENT, rheumatology and clinical immunology, internal medicine, interventional radiology, diabetology, endocrinology, general surgery, infectious disease, dermatology, thoracic surgery, psychiatry, plastic and reconstructive surgery, transfusion medicine, clinical psychology, anesthesiology, and tele medicine services. In addition, the company operates clinical immunology allergy, bone marrow transplantation, hair transplant, andrology, fertility, alzheimer, arthroscopy, bone and joint, breast, dialysis, female urology, IUI, IVF, joint replacement, kidney health and transplant, ICU, spine, stroke, TAVR/TAVI, hepatobiliary surgery, and trauma centers, as well as pain and wellness clinics. Further, it provides bariatric, thoracic, oral maxillofacial, and endovascular surgery services. Krishna Institute of Medical Sciences Limited was incorporated in 1973 and is based in Secunderabad, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters41.7%
Institutions39.0%
Public & other19.2%

76 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

Margin has compressed by about 9.1 points over the period — profitability is trending down.

Net margin trend15.3% → 6.2%

Margin has compressed by about 9.1 points over the period — profitability is trending down.

Growth qualityrev 21% · PAT -10%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹1,259 Cr · EPS 2.51

Est. earnings growth +49.8%

Next fiscal year

Rev ₹6,154 Cr · EPS 17.08

Est. earnings growth +61.1%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹575.8052-wk range₹858.00

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹31,389 Cr

Day change

-0.5%

Fwd P/E

45.9

P/B

14.0

Beta

0.18

Revenue (FY2026)

₹3,905 Cr

Net margin

6.2%

Revenue CAGR (3y)

+21.1%

Profit CAGR (3y)

-10.5%

Net profit (FY2026)

₹241 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about KIMS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹3,905 Cr	₹241 Cr	6.2%
FY2025	₹3,035 Cr	₹385 Cr	12.7%
FY2024	₹2,498 Cr	₹310 Cr	12.4%
FY2023	₹2,198 Cr	₹336 Cr	15.3%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	₹1,075 Cr	₹43 Cr	4.0%
2025Q4	₹998 Cr	₹53 Cr	5.4%
2025Q3	₹961 Cr	₹67 Cr	7.0%
2025Q2	₹872 Cr	₹79 Cr	9.0%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.